Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. NVDA
6. IBM
7. PRIM
8. SPY
9. ACN
10. BLZE

Go back to Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
(NASDAQ: VRDN) Delayed: 17.60 -0.03 (0.17%)
Previous Close $17.63    52 Week High $ 
Open $17.29    52 Week Low $ 
Day High $17.73    P/E N/A 
Day Low $17.27    EPS $ 
Volume 945,711